The following article is a part of conference coverage from Psych Congress 2020 Virtual Experience, held virtually from September 10 to 13, 2020. The team at at Psychiatry Advisor will be reporting on the latest news and research conducted by leading experts in psychiatry. Check back for more from the Psych Congress 2020.

 

Solriamfetol was found to improve driving performance in patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA), according to study results presented at Psych Congress 2020, held online from September 10 to 13, 2020.

Researchers conducted a randomized, double-blind, crossover study (ClinicalTrials.gov Identifier: NCT02806895) to assess the effects of solriamfetol on driving performance in patients with EDS with OSA, Over a 7-day period, they assessed on-road driving performance at 2 and 6 hours after administration of solriamfetol 150 mg/d for 3 days followed by 300 mg/d for 4 days or placebo. The primary study outcome was a standard deviation of lateral position (SDLP), a measure of “weaving,” calculated 2 hours following medication administration.

The study cohort included 34 patients (88% men) with OSA, with a mean age of 52 years. Patients had a mean Epworth Sleepiness Scale score of 14.4 and a Maintenance of Wakefulness Test sleep latency score of 14.3 minutes. Results showed that 2 hours after medication administration, SDLP was significantly lower for patients who received solriamfetol vs placebo (least squares [LS] mean, 18.83 vs 19.92 cm, respectively; LS mean difference, -1.08 cm; 95% CI, -1.85 to -0.32 cm; P =.0062). Similar results of a lower SDLP were observed 6 hours after administration of solriamfetol vs placebo (LS mean, 19.24 vs 20.04 cm, respectively; LS mean difference, -0.80 cm; 95% CI, -1.58 to -0.03 cm; P =.0432).


Continue Reading

Headache, nausea, insomnia, dizziness, and agitation were the most commonly reported adverse events.

Overall, the researchers concluded that solriamfetol 300 mg/d improved SDLP as measured at 2 and 6 hours following medication administration in patients with EDS associated with OSA.

Disclosure: This study was supported by Jazz Pharmaceuticals, Inc., which employs a number of the study authors. Please refer to the poster for a full list of disclosures. 

Visit Psychiatry Advisor’s meetings section for complete coverage of Psych Congress 2020.

Reference

Vinckenbosch F, Asin J, de Vries N, et al. Effects of solriamfetol on driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnea. Presented at Psych Congress 2020 Virtual Experience; September 10 to 13, 2020. Poster 146. 

This article originally appeared on Psychiatry Advisor